CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: Data from the DEBATE study

American Journal of PharmacoGenomics

Volumn 5, Issue 3, 2005, Pages 191-195

  Kivistö, Kari T ^a   Niemi, Mikko ^a,b   Schaeffeler, Elke ^a   Pitkälä, Kaisu ^c   Tilvis, Reijo ^c   Fromm, Martin F ^a,d   Schwab, Matthias ^a   Lang, Florian ^e   Eichelbaum, Michel ^a   Strandberg, Timo ^c  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A5;

AGED; ANAMNESIS; ARTICLE; BLOOD PRESSURE REGULATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FEMALE; FINLAND; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HUMAN; HYPERTENSION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ALLELES; BASE SEQUENCE; BLOOD PRESSURE; CYTOCHROME P-450 ENZYME SYSTEM; DNA; EVIDENCE-BASED MEDICINE; FEMALE; FINLAND; GENOTYPE; HUMANS; HYPERTENSION; MALE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 22244451696     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200505030-00005     Document Type: Article

References (29)

1. Givens RC, Lin YS, Dowling AL, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003; 95: 1297-300
2. Langaee TY, Givens RC, Sloan A, et al. Association of CYP3A5*3, *6, and *7 polymorphisms with hypertension [abstract]. Clin Pharmacol Ther 2004; 75: 13
3. Ho H, Pinto A, Hall SD, et al. Association between the CYP3A5 genotype and blood pressure. Hypertension 2005; 45: 294-8
4. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-9
5. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91
6. Schuetz EG, Schuetz JD, Grogan WM, et al. Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch Biochem Biophys 1992; 294: 206-14
7. Haehner BD, Gorski JC, Vandenbranden M, et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 1996; 50: 52-9
8. Watlington CO, Kramer LB, Schuetz EG, et al. Corticosterone 6 beta-hydroxylation correlates with blood pressure in spontaneously hypertensive rats. Am J Physiol 1992; 262: F927-31
9. Ghosh S, Grogan WM, Basu A, et al. Renal corticosterone 6 beta-hydroxylase in the spontaneously hypertensive rat. Biochim Biophys Acta 1993; 1182: 152-6
10. Ghosh SS, Basu AK, Ghosh S, et al. Renal and hepatic family 3A cytochromes P450 (CYP3A) in spontaneously hypertensive rats. Biochem Pharmacol 1995; 50: 49-54
11. Wrighton SA, Brian WR, Sari MA, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38: 207-13
12. Duncan RL, Grogan WM, Kramer LB, et al. Corticosterone's metabolite is an agonist for Na+ transport stimulation in A6 cells. Am J Physiol 1988; 255: F736-48
13. Strandberg TE, Pitkälä K, Berglind S, et al. Multifactorial cardiovascular disease prevention in patients aged 75 years and older: a randomized controlled trial: Drugs and Evidence Based Medicine in the Elderly (DEBATE) Study. Am Heart J 2001; 142: 945-51
14. Strandberg TE, Pitkälä K, Berglind S, et al. Possibilities of multifactorial cardiovascular disease prevention in patients aged 75 and older: a randomized controlled trial: Drugs and Evidence Based Medicine in the Elderly (DEBATE) Study. Eur Heart J 2003; 24: 1216-22
15. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003; 43: 285-307
16. Tirona RG, Leake BF, Merino G, et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001; 276: 35669-75
17. Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14: 429-40
18. Furuno T, Landi MT, Ceroni M, et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2002; 12: 529-34
19. King BP, Leathart JB, Mutch E, et al. CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol 2003; 55: 625-9
20. Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 (OATP1B1) is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. In press
21. Amudha K, Wong LP, Choy AM, et al. Ethnicity and drug therapy for hypertension. Curr Pharm Des 2003; 9: 1691-701
22. Stein CM, Lang CC, Xie HG, et al. Hypertension in black people: study of specific genotypes and phenotypes will provide a greater understanding of interindividual and interethnic variability in blood pressure regulation than studies based on race. Pharmacogenetics 2001; 11: 95-110
23. Schwartz GL, Turner ST. Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics 2004; 4: 151-60
24. Watson Jr B. Genetics of the kidney and hypertension. Curr Hypertens Rep 2003; 5: 273-6
25. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82: 131-85
26. Zhao X, Imig JD. Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr Drug Metab 2003; 4: 73-84
27. Rifkind AB, Lee C, Chang TK, et al. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch Biochem Biophys 1995; 320: 380-9
28. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension 1996; 27: 481-90
29. Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243-72